Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension

European Journal of Clinical Pharmacology

Volumn 69, Issue 12, 2013, Pages 2027-2036

  Quinaglia, Thiago ^a   De Faria, Ana Paula C ^a   Fontana, Vanessa ^a   Barbaro, Natália R ^a   Sabbatini, Andréa R ^a   Sertório, Jonas T ^b   Demacq, Caroline ^c   Tanus Santos, José E ^b   Moreno, Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Novartis Biociencias SA   (Brazil)

Author keywords

Diastolic function; Endothelial dysfunction; ENOS polymorphism; Hemodynamic pattern; Resistant hypertension; Sildenafil

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRITE; PLACEBO; SILDENAFIL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DIZZINESS; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; ENDOTHELIAL DYSFUNCTION; ENZYME POLYMORPHISM; FEMALE; FLOW MEDIATED DILATION; HEART OUTPUT; HEMODYNAMICS; HUMAN; LEFT VENTRICULAR DIASTOLIC FUNCTION; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; PRIORITY JOURNAL; RESISTANT HYPERTENSION; VASCULAR RESISTANCE;

AGED; ARTERIAL PRESSURE; CROSS-OVER STUDIES; CYCLIC GMP; DRUG RESISTANCE; FEMALE; GENOTYPE; HEMODYNAMICS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SINGLE-BLIND METHOD; SULFONES; VENTRICULAR FUNCTION, LEFT;

EID: 84892365013     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1571-z     Document Type: Article

References (51)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117:e510-526
2. DiBona GF (2000) Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function. Hypertension 36:1083-1088
3. Sowers JR, Whaley-Connell A, Epstein M (2009) Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 150:776-783
4. Narkiewicz K, van de Borne PJ, Montano N, Dyken ME, Phillips BG, Somers VK (1998) Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 97:943-945
5. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E (2006) Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48:787-796
6. Yugar-Toledo JC, Tanus-Santos JE, Sabha M, Sousa MG, Cittadino M, Tacito LH, Moreno H Jr (2004) Uncontrolled hypertension, uncompensated type II diabetes, and smoking have different patterns of vascular dysfunction. Chest 125:823-830
7. Folkow B, Ely D (1998) Importance of the blood pressure-heart rate relationship. Blood Press 7:133-138
8. Clement DL, Duprez D (1984) Circulatory changes in muscle and skin arteries in primary hypertension. Hypertension 6:III122-127
9. Grocott-Mason R, Anning P, Evans H, Lewis MJ, Shah AM (1994) Modulation of left ventricular relaxation in isolated ejecting heart by endogenous nitric oxide. Am J Physiol 267:H1804-1813
10. Grocott-Mason R, Fort S, Lewis MJ, Shah AM (1994) Myocardial relaxant effect of exogenous nitric oxide in isolated ejecting hearts. Am J Physiol 266:H1699-1705
11. Kruger M, Kotter S, Grutzner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA (2009) Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 104:87-94
12. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, Boulden BM, Widder J, Fredd S, Bernstein KE, Wolska BM, Dikalov S, Harrison DG, Dudley SC Jr (2010) Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 121:519-528
13. Wilson Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B, Hu B, Troughton RW, Klein AL, Hazen SL (2008) Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J 29:2506-2513
14. Bronzwaer JG, Paulus WJ (2008) Nitric oxide: the missing lusitrope in failing myocardium. Eur Heart J 29:2453-2455
15. Paulus WJ, Vantrimpont PJ, Shah AM (1994) Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 89:2070-2078
16. Oliver JJ, Melville VP, Webb DJ (2006) Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 48:622-627
17. Schwartz BG, Kloner RA (2010) Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation 122:88-95
18. Oliver JJ, Dear JW, Webb DJ (2010) Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatmentresistant hypertension. Hypertension 56:62-67
19. Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944-12955
20. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238-248
21. Ferreira-Melo SE, Demacq C, Lacchini S, Krieger JE, Irigoyen MC, Moreno H (2011) Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arterioles. Clinics (Sao Paulo) 66:1253-1258
22. Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebocontrolled study. Circ Heart Fail 4:8-17
23. Miyamoto Y, Saito Y, Nakayama M, Shimasaki Y, Yoshimura T, Yoshimura M, Harada M, Kajiyama N, Kishimoto I, Kuwahara K, Hino J, Ogawa E, Hamanaka I, Kamitani S, Takahashi N, Kawakami R, Kangawa K, Yasue H, Nakao K (2000) Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a-786T-> C mutation associated with coronary spastic angina. Hum Mol Genet 9:2629-2637
24. Groppelli A, Omboni S, Parati G, Mancia G (1992) Evaluation of noninvasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24-h intra-arterial blood pressure. Hypertension 20:227-232
25. Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS, Johnson AL (1975) Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet 1:1205-1207
26. Tanus-Santos JE, Desai M, Flockhart DA (2001) Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 11:719-725
27. Dejam A, Hunter CJ, Pelletier MM, Hsu LL, Machado RF, Shiva S, Power GG, Kelm M, Gladwin MT, Schechter AN (2005) Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood 106:734-739
28. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257-265
29. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115
30. Sahn DJ, DeMaria A, Kisslo J, Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072-1083
31. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-1463
32. Rivas-Gotz C, Manolios M, Thohan V, Nagueh SF (2003) Impact of left ventricular ejection fraction on estimation of left ventricular filling pressures using tissue Doppler and flow propagation velocity. Am J Cardiol 91:780-784
33. Peñaz J (1973) Photoelectric measurement of blood pressure, volume and flow in the finger. Digest of the 10th International Conference on Medicine and Biological Engineering, Dresden, p 104
34. Gerin W, Pieper C, Pickering TG (1993) Measurement reliability of cardiovascular reactivity change scores: a comparison of intermittent and continuous methods of assessment. J Psychosom Res 37:493-501
35. Parati G, Casadei R, Groppelli A, Di Rienzo M, Mancia G (1989) Comparison of finger and intra-arterial blood pressure monitoring at rest and during laboratory testing. Hypertension 13:647-655
36. Imholz BP, van Montfrans GA, Settels JJ, van der Hoeven GM, Karemaker JM, Wieling W (1988) Continuous non-invasive blood pressure monitoring: reliability of Finapres device during the Valsalva manoeuvre. Cardiovasc Res 22:390-397
37. Imholz BP, Langewouters GJ, van Montfrans GA, Parati G, van Goudoever J, Wesseling KH, Wieling W, Mancia G (1993) Feasibility of ambulatory, continuous 24-h finger arterial pressure recording. Hypertension 21:65-73
38. Jackson G, Benjamin N, Jackson N, Allen MJ (1999) Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83:13C-20C
39. Jackson G, Keltai M, Csanady M, Edes I, Bellamy GR, Widimsky P, Lisa L, Gillies H (2005) Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction. J Sex Med 2:407-414
40. Nichols DJ, Muirhead GJ, Harness JA (2002) Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53(Suppl 1):5S-12S
41. Leite-Moreira AF, Correia-Pinto J, Gillebert TC (1999) Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res 43:344-353
42. Brutsaert DL, Sys SU, Gillebert TC (1993) Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol 22:318-325
43. Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich FV, Burnett JC Jr, Linke WA, Redfield MM (2011) Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 124:2882-2891
44. Ramirez-Correa GA, Murphy AM (2007) Is phospholamban or troponin I the "prima donna" in beta-adrenergic induced lusitropy? Circ Res 101:326-327
45. Paulus WJ, Bronzwaer JG (2004) Nitric oxide's role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol 287:H8-13
46. Yugar-Toledo JC, Ferreira-Melo SE, Consolim-Colombo FM, Irigoyen MC, Coelho OR, Moreno H Jr (2007) Cyclic guanosine monophosphate phosphodiesterase-5 inhibitor promotes an endothelium NO-dependent-like vasodilation in patients with refractory hypertension. Nitric Oxide 16:315-321
47. Figueiredo VN, Yugar-Toledo JC, Martins LC, Martins LB, de Faria AP, de Haro Moraes C, Sierra C, Coca A, Moreno H (2012) Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure. Blood Press 21:31-38
48. Abe K, Nakayama M, Yoshimura M, Nakamura S, Ito T, Yamamuro M, Sakamoto T, Miyamoto Y, Yoshimasa Y, Saito Y, Nakao K, Yasue H, Ogawa H (2005) Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relationwith the-786T>C polymorphism. Pharmacogenet Genomics 15:329-336
49. Nagassaki S, Sertorio JT, Metzger IF, Bem AF, Rocha JB, Tanus-Santos JE (2006) eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med 41:1044-1049
50. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach RF, Rego EM, Tanus-Santos JE (2007) Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 193:438-444
51. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E (2003) Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 16:834-839